Introduction {#s1}
============

In recent years, our understanding of innate immune recognition of microbial components and its critical role in host defense against infection has grown considerably. The discovery of Toll-like receptors (TLRs) and other classes of signal-transducing innate immune receptors exemplifies a model of pathogen recognition by germline-encoded pattern-recognition receptors (PRRs) of the innate immune system that detect components of invading pathogens, termed pathogen-associated molecular patterns (PAMPs) ([@bib25]; [@bib4]; [@bib28], [@bib29]). Upon recognition of PAMPs, these receptors activate NF-κB, interferon regulatory factors (IRFs) and other transcription factors, which then induce the transcription of cognate target genes ([@bib53]; [@bib24]). This results in the evocation of innate immune responses that also instruct subsequent innate immune responses. Dead or injured cells also recruit and activate innate inflammatory cells in the absence of infection through recognition by PRRs of released self-derived molecules termed damage-associated molecular patterns (DAMPs) ([@bib3]; [@bib43]). To date, the role of innate immune receptors in anti-tumor innate immune response is unknown.

It has been well-established that natural killer (NK) cells are essential effector cells of the innate arm of the immune system to control virus infections and tumor developments by exerting cytotoxicity of target cells ([@bib56]). NK cells are sub-classified into circulating conventional NKs (cNKs) and tissue-resident NKs (trNKs) ([@bib50]). Thus far, most of the functional studies on NK cells have focused on cNKs, which are found to be abundant in the spleen. In view of the critical role of cNKs (referred to as NKs hereafter unless stated otherwise) in anti-tumor innate immunity, the interesting issue for whether PRRs expressed on NK and/or other immune cells may recognize tumor cells for the enhancement of tumoricidal activity of NK cells. It has been reported that cell-to-cell contact between dendritic cells (DCs) and resting NK cells causes an enhancement of NK cell-mediated cytolytic activity against tumor cells ([@bib13]); however, the involvement of PRRs in this context remains unknown. Of note, some TLRs appear to have the opposite effect ([@bib42]; [@bib41]). For instance, activation of TLR2 and TLR6 in macrophages enhances metastasis of tumor cells, wherein receptor activation is mediated by tumor cell-derived versican, an extracellular matrix proteoglycan that is up-regulated in many tumor cells ([@bib30]).

During our studies on the IRF family of transcription factors in the context of regulation of PRR signaling and oncogenesis, we observed that mice genetically deficient for IRF5 (IRF5-deficient mice) show extensive lung metastasis of the B16F1 melanoma cells (hereafter referred to as B16 cells), a consequence reported to be controlled by NK cells. Since IRF5 is known to be activated by TLRs and other classes of PRRs, we asked whether any of these PRRs is involved in this process in the context of NK cell-mediated control of tumor cells. In light of the tumor-promoting effect by TLRs ([@bib42]; [@bib41]), we hypothesized that another class of PRRs expressed on the cell surface may be involved in the recognition of tumor cells for the NK cell-mediated anti-tumor response. Dectin-1, a C-type lectin receptor (CLR) family member known to recognize β-glucans of fungal cell wall ([@bib6]), was of particular interest since (i) it is highly expressed in macrophages and DCs ([@bib17]) and (ii) IRF5 is involved in Dectin-1 signaling for anti-fungal innate immune response ([@bib10]).

We show here that Dectin-1 expressed on DCs and macrophages critically contributes to the enhancement of NK-mediated killing of tumor cells. Further, we demonstrate that IRF5 is activated by Dectin-1 signaling in these immune cells and that this Dectin-1-IRF5 pathway constitutes a critical limb for their orchestration of NK cells. We also provide evidence that tumor cell-mediated Dectin-1 signaling is instigated by receptor recognition of N-glycan structures on the surface of some but not all tumor cells, which we propose to term tumor-associated molecular patterns (TAMPs). Finally, the in vivo significance of these observations is validated by the massive growth of the TAMP-expressing tumors in mice genetically deficient for either Dectin-1 or IRF5.

We discuss our results revealing a new facet of the CLR family of receptors in the orchestration of anti-tumor innate immune responses as well as future prospects of innate recognition and control of tumor cells, which may have clinical implications.

Results {#s2}
=======

A requirement for IRF5 in innate immune responses against B16 melanoma {#s2-1}
----------------------------------------------------------------------

Within the IRF family of transcription factors, several members including IRF3, IRF5 and IRF7 are particularly well-known for the pivotal roles they serve in the innate immune receptor-mediated gene induction programme ([@bib19]). Here, we challenged mice deficient in these individual transcription factors with the lung metastasis model of B16F1 melanoma cells (hereafter referred to as B16 unless stated otherwise). As shown in [Figure 1A,B](#fig1){ref-type="fig"}, we observed markedly enhanced metastasis of B16 cells in the lungs of mutant mice deficient in the *Irf5* gene (hereafter IRF5-deficient mice). Massive tumor growth was also observed when B16 cells were subcutaneously injected into the mutant mice ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).10.7554/eLife.04177.003Figure 1.Critical contribution of IRF5 to the enhancement of NK cell-mediated anti-tumor responses.(**A**) Selective contribution of IRF5 in the suppression of lung metastasis of B16F1 cells. Number of metastasized colonies in lungs from wild-type (WT), *Irf3*^−/−^, *Irf5*^−/−^, or *Irf7*^−/−^ mice 14 days after intravenous injection of 1 × 10^6^ of B16F1 cells. Means are indicated as black bars. \*p \< 0.05 by Student\'s *t* test. (**B**) Representative images of lungs from WT or *Irf5*^−/−^ mice 14 days after intravenous injection of 2 × 10^6^ of B16F1 cells. (**C**) In vitro killing assay of immune cells from WT or *Irf5*^−/−^ mice against B16F1 cells. Whole splenocytes (left panel), purified NK cells (middle panel), or NK-depleted splenocytes (right panel) from WT or *Irf5*^*−/−*^ mice are mixed with ^51^Cr-labeled target B16F1 cells at the indicated ratios. 4 hr later, ^51^Cr radioactivity released from target cells was monitored. E/T: effector/target cell ratio. (**D**) Purified NK cells (WT; 1 × 10^5^ cells) without or with 1 × 10^5^, 2 × 10^5^, or 4 × 10^5^ of WT splenic CD11c^+^, CD11b^+^, T, or B cells were subjected to in vitro killing assay for B16F1 cells. Target cell lysis was measured by co-culturing target cells and myeloid cells, with (total values) or without NK cells (background values), and background values were subtracted from the total values. Each background lysis was less than 6% of maximum release. The calculated percentage of cytotoxicity was represented as Net lysis (%). In all in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used (**C** and **D**). All in vitro killing assays were performed at least three times with high reproducibility. Represented as means ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.003](10.7554/eLife.04177.003)10.7554/eLife.04177.004Figure 1---figure supplement 1.Critical role of IRF5 in the suppression of tumor growth.Tumor growth in WT and *Irf5*^−/−^ mice. Tumor volume of WT or *Irf5*^*−/−*^ mice was monitored at the indicated days after subcutaneous injection of 1 × 10^5^ of B16F1 cells. Represented as means ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.004](10.7554/eLife.04177.004)10.7554/eLife.04177.005Figure 1---figure supplement 2.Requirement of IRF5 in myeloid cells for the suppression of tumor metastasis.(**A**) Tumor metastasis in bone marrow chimera mice. Chimera mice were generated using WT, *Irf5*^*−/−*^, and C57BL/6-Ly5.1 (Ly5.1) mice. Numbers of metastasized colonies in lungs from the bone marrow chimera mice were counted 14 days after intravenous injection with 1 × 10^6^ of B16F1 cells. Means are indicated as black bars. \*p \< 0.05 by Student\'s *t* test. (**B**) Tumor metastasis in WT or *Rag1*^*−/−*^ mice. Numbers of metastasized colonies in lungs from WT or *Rag1*^*−/−*^ mice were counted 14 days after intravenous injection with 1 × 10^6^ of B16F1 cells. Means are indicated as black bars.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.005](10.7554/eLife.04177.005)10.7554/eLife.04177.006Figure 1---figure supplement 3.Involvement of IRF5 in CD11b^+^ and CD11c^+^ cells to the enhancement of NK cell-mediated anti-tumor responses.Requirement of IRF5 in myeloid cells for the enhancement of NK cell\'s in vitro killing activity. In vitro killing activities of purified NK cells (WT; 1 × 10^5^ cells) against B16F1 cells were monitored in the absence or presence of 1 × 10^5^, 2 × 10^5^, or 4 × 10^5^ of WT or *Irf5*^*−/−*^ splenic CD11b^+^ (left panel) or CD11c^+^ (right panel) cells. The percentage of cytotoxicity was calculated as described in the legend of [Figure 1D](#fig1){ref-type="fig"} and represented as Net lysis (%). Each background lysis was less than 6% of maximum release. Represented as means ± SD. \*p \< 0.05 by Student's *t* test. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used. All in vitro killing assays were performed at least three times and the results were highly reproducible.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.006](10.7554/eLife.04177.006)10.7554/eLife.04177.007Figure 1---figure supplement 4.Contribution of DCs and macrophages to the NK cell-mediated tumor killing.The effect of various myeloid cells on the enhancement of NK cell killing activities. In vitro killing activities of purified NK cells (WT; 1 × 10^5^ cells) were monitored in the absence or presence of 1 × 10^5^, 2 × 10^5^, or 4 × 10^5^ of splenic CD8^+^CD11c^+^ (left panel), CD8^--^CD11c^+^ (middle panel), or CD11c^−^CD11b^+^ (right panel) cells. CD11c^−^CD11b^+^ cells were purified from diphtheria toxin-treated CD11c-DTR mice. The percentage of cytotoxicity was calculated as described in the legend of [Figure 1D](#fig1){ref-type="fig"} and represented as Net lysis (%). Each background lysis was less than 5% of maximum release. Represented as means ± SD. 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used as target cells. All in vitro killing assays were performed at least three times and the results were highly reproducible.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.007](10.7554/eLife.04177.007)

To examine the contribution of immune cells, we next conducted bone marrow transplantation and found that IRF5 expression specifically in bone marrow-derived cells critically contributes to the suppression of the tumor cell metastasis ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). Since the marked B16 lung metastasis was not observed in mice deficient in T and B lymphocyte development ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), we next examined the contribution of IRF5 in anti-tumor innate immune response, wherein NK cells are best known for their direct anti-tumor cytotoxicity ([@bib49]). When whole splenocytes, of which about 3% are resting NK cells in both wild-type (WT) and IRF5-deficient mice ([@bib51]), were subjected to an in vitro killing assay ([@bib8]) (^51^Cr release assay) for B16 cells, a notable decrease of killing activity was observed in those from IRF5-deficient mice ([Figure 1C](#fig1){ref-type="fig"}; left panel). Interestingly, however, when NK cells were purified from these splenocytes and then subjected to the killing assay, the lack of IRF5 did not affect the NK activity ([Figure 1C](#fig1){ref-type="fig"}; middle panel). Since the killing activity is entirely abrogated by NK cell depletion in both WT and mutant splenocytes ([Figure 1C](#fig1){ref-type="fig"}; right panel), these results indicate there is a critical contribution of non-NK cells within the total splenocyte population for which IRF5 is critical for the full-blown killing activity of NK cells.

Consistent with this notion, when purified NK cells were co-cultured with CD11c^+^ DCs and macrophage-enriched CD11b^+^ cells from splenocytes (hereafter referred to as co-culture assay), a dose-dependent and significant increase in NK killing activity was observed, whereas T or B lymphocytes had no such effect ([Figure 1D](#fig1){ref-type="fig"}). Of note, a marked reduction of the NK killing activity was observed when CD11b^+^ or CD11c^+^ cells from IRF5-deficient mice were used in lieu of those from WT mice in the co-culture assay ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). The enhancement of NK killing activity was also made in another co-culture assay, wherein CD8^+^CD11c^+^, CD8^−^CD11c^+^, or CD11c^−^CD11b^+^ cells purified from splenocytes were used, indicating that both DCs and macrophages participate in the enhancement of NK cell-mediated killing activity ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}).

Contribution of the Dectin-1-IRF5 pathway in NK cell-mediated anti-tumor response {#s2-2}
---------------------------------------------------------------------------------

The above observations prompted us to investigate the contribution of innate immune receptor(s) that recognizes B16 cells and activate IRF5 for the NK-mediated killing of the tumor cells. Although IRF5 is best known as a transcription factor activated by TLR signaling, we observed that splenocytes from mice deficient in MyD88, the common adapter for all TLRs, shows killing activity against B16 cells at a rate even slightly higher than those from WT mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We then focused our attention on Dectin-1, a member of the CLR family, which is expressed on the cell surface of innate immune cells. In fact, Dectin-1, known to recognize β-glucans of fungal cell wall ([@bib6]), is widely expressed by DCs and macrophages and the activation of IRF5 by the Dectin-1-Syk pathway has been implicated in the induction of type I interferon-β (IFN-β) gene upon fungal infection ([@bib10]; [@bib31]; [@bib2]; [@bib5]; [@bib20]).

We first examined whether IRF5 is activated in splenocytes through recognition of and signaling induced by B16 cells in a Dectin-1-dependent manner. Interestingly, we observed nuclear translocation of IRF5, a hallmark of its activation ([@bib19]), following incubation of WT splenocytes with B16 cells (in 50 to 1 or 100 to 1 cell ratio), but not in splenocytes from mice deficient in the *Clec7a* gene that encodes Dectin-1 (hereafter Dectin-1-deficient mice), indicating there is a Dectin-1 signal-dependent IRF5 activation by the tumor cells ([Figure 2A](#fig2){ref-type="fig"}). Of note, IRF5 activation by B16 cells was not inhibited by FK506, suggesting there is a calcineurin-independent pathway for this activation ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). As such, these data support a Dectin-1 signal-dependent IRF5 activation by tumor cells.10.7554/eLife.04177.008Figure 2.Critical role of Dectin-1 signaling in DCs and macrophages for IRF5 activation by and NK cell-mediated killing against B16F1 cells.(**A**) Nuclear translocation of IRF5 in WT or *Dectin-1*^−/−^ splenocytes (5 × 10^7^ cells) co-incubated with B16F1 cells (5 × 10^5^ or 1 × 10^6^ cells) or stimulated with curdlan (30 µg/ml) for 6 hr. Nuclear protein fraction from the culture was analyzed by immunoblotting for IRF5 and USF-2. USF-2 was used as a nuclear marker protein. (**B**) In vitro killing activity of whole splenocytes from WT or *Dectin-1*^−/−^ mice against B16F1 cells. (**C**) In vitro killing activity of purified NK cells (WT; 1 × 10^5^ cells) against B16F1 cells was assessed in the absence or presence of 1 × 10^5^, 2 × 10^5^, or 4 × 10^5^ of WT or *Dectin-1*^−/−^ splenic CD11b^+^ (left panel) or CD11c^+^ (right panel) cells. The percentage of cytotoxicity was calculated as noted in the legend of [Figure 1D](#fig1){ref-type="fig"} and represented as Net lysis (%). Each background lysis was less than 6% of maximum release. In all in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used (**B** and **C**). All in vitro killing assays were performed at least three times with high reproducibility. Represented as means ± SD. \*p \< 0.05 by Student\'s *t* test. Of note, we could not found mRNA induction for typical inflammatory and cytotoxic mediators in the co-culture system, wherein the ratio of B16F1 cells, DCs, and NK cells is 1:30:10 ([Figure 2---figure supplement 8](#fig2s8){ref-type="fig"}). As such, from these analyses, it seems unlikely that Dectin-1 signaling in DCs affects the expression of these molecules in NK cells. (**D**) Number of metastasized colonies in lungs from WT or *Dectin-1*^−/−^ mice intravenously injected with 1 × 10^6^ of B16F1 cells. Means are indicated as black bars. \*p \< 0.05 by Student\'s *t* test. (**E**) Representative images of lungs from WT or *Dectin-1*^−/−^ mice 14 days after intravenous injection of 2 × 10^6^ of B16F1 cells.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.008](10.7554/eLife.04177.008)10.7554/eLife.04177.009Figure 2---figure supplement 1.Dispensable role of MyD88 in anti-tumor killing activity of NK cells.In vitro killing activity of WT or *Myd88*^*−/−*^ splenocytes against B16F1 cells. Represented as means ± SD. E/T: effector/target cell ratio. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used. In vitro killing assays were performed at least three times, and the results were highly reproducible.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.009](10.7554/eLife.04177.009)10.7554/eLife.04177.010Figure 2---figure supplement 2.Effect of FK506 treatment on IRF5 activation in splenocytes.Nuclear translocation of IRF5 of WT splenocytes (5 × 10^7^ cells) co-incubated with B16F1 cells (1 × 10^6^ cells) for 6 hr in the absence or presence of 50 or 500 nM of FK506. Nuclear protein extracts from the culture were analyzed by immunoblotting for IRF5 and USF-2.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.010](10.7554/eLife.04177.010)10.7554/eLife.04177.011Figure 2---figure supplement 3.Minor effects of Dectin-1 expressed in NK cells on the tumor killing activity.(**A**) In vitro killing activity of purified NK cells from WT or *Dectin-1*^*−/−*^ mice against B16F1 cells. Represented as means ± SD. E/T: effector/target cell ratio. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used. In vitro killing assays were performed at least three times, and the results were highly reproducible. (**B**) qRT-PCR analysis of *Dectin-1* mRNA in WT splenic CD11b^+^ cells, CD11c^+^ cells and NK cells, and MEFs. Results are presented as relative to the expression of *Gapdh* mRNA. Represented as means ± SD. ND, none detected. (**C**) Expression levels of *Dectin-1* mRNA in myeloid cells from liver and lungs. CD11b^+^F4/80^+^ cells and CD11c^+^ cells from liver and lung were isolated by cell sorting. Results are presented as relative to the expression of *Gapdh* mRNA. Represented as means ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.011](10.7554/eLife.04177.011)10.7554/eLife.04177.012Figure 2---figure supplement 4.Essential role of Dectin-1 in the suppression of tumor growth.Tumor growth in WT and *Dectin-1*^−/−^ mice. Tumor volume of WT or *Dectin-1*^*−/−*^ mice was monitored at the indicated days after subcutaneous injection of 1 × 10^5^ of B16F1 cells. Represented as means ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.012](10.7554/eLife.04177.012)10.7554/eLife.04177.013Figure 2---figure supplement 5.Contribution of Dectin-1 and IRF5 to the control of tumor metastasis.Number of metastasized colonies in the lungs from WT, *Irf5*^*−/−*^, or *Dectin-1*^*−/−*^ mice. Mice were intravenously injected with 1 × 10^6^ of B16F1 cells and, 14 days later, the number of metastasized colonies in lungs was measured. Means are indicated as black bars. \*p \< 0.05 (WT *vs Irf5*^−/−^, WT *vs Dectin-1*^−/−^, *Irf5*^−/−^ *vs Dectin-1*^−/−^) by Student\'s *t* test.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.013](10.7554/eLife.04177.013)10.7554/eLife.04177.014Figure 2---figure supplement 6.Dispensable role of Dectin-1 in NK-cell-independent tumor suppression.NK-depleted WT, or NK-depleted *Dectin-1*^−/−^ mice were intravenously injected with 1 × 10^6^ of B16F1 cells. After 14 days, the numbers of metastasized colonies were counted in the lungs of each mouse. This result suggests that NK cells are indeed the effector cells and that Dectin-1 signaling in DCs and macrophages contributes to NK cell-mediated tumor killing. Means are indicated as black bars. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.014](10.7554/eLife.04177.014)10.7554/eLife.04177.015Figure 2---figure supplement 7.Normal population and functions of Dectin-1-deficient NK cells.(**A**) The population of splenic NK cells in *Dectin-1*^−/−^ mice. Splenocytes were isolated from WT and *Dectin-1*^−/−^ mice. The NK cell population (percentage of total cells) was then analyzed by flow cytometry using anti-DX5 and anti-CD3ε antibodies. Represented as means ± SD. NS, not significant. (**B**) IL12-induced IFN-γ production in NK cells. Purified NK cells (WT or *Dectin-1*^−/−^; 5 × 10^4^ cells) were stimulated with 10 or 100 ng/ml of IL12. IFN-γ levels in the cultured supernatants were measured by ELISA 24 hr after IL12 stimulation. Represented as means ± SD. NS, not significant. ND, none detected. (**C**) Viral loads in the spleens of WT and *Dectin-1*^*−/−*^ mice after MCMV infection. WT, *Dectin-1*^*−/−*^, and NK-depleted WT mice were intraperitoneally infected with MCMV (5 × 10^3^ pfu). Mice were sacrificed 3 days after infection and MCMV titers were then examined by plaque forming assay. Means are indicated as black bars; NS, not significant. (**D**) Survival of the WT (n = 4), *Dectin-1*^*−/−*^ (n = 4), and NK-depleted WT mice (n = 4) after MCMV infection. Mice were intraperitoneally infected with MCMV (3 × 10^5^ pfu) and their survival was monitored at the indicated periods.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.015](10.7554/eLife.04177.015)10.7554/eLife.04177.016Figure 2---figure supplement 8.Expression levels of cytotoxic mediators and inflammatory cytokines in co-culture system.NK cells (WT; 1 × 10^5^ cells) and WT or *Dectin-1*^*−/−*^ splenic CD11c^+^ cells (3 × 10^5^ cells) were co-cultured with B16F1 cells (1 × 10^4^ cells). Total RNA was isolated at time zero and 4 hr after the co-culture and then mRNA expression levels for Granzyme B (*Gzmb*), Perforin-1 (*Prf1*), IFN-γ (*Ifng*), IL-6 (*Il6*), and TNF-α (*Tnf*) were analyzed by qRT-PCR analysis. Results are presented relative to the expression of *Gapdh* mRNA. Represented as means ± SD.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.016](10.7554/eLife.04177.016)

Requirement of Dectin-1 in DCs and macrophages for in vitro tumoricidal activity of NK cells {#s2-3}
--------------------------------------------------------------------------------------------

Consistent with the above notion, a dramatic reduction of in vitro tumoricidal activity was observed with Dectin-1-deficient splenocytes ([Figure 2B](#fig2){ref-type="fig"}). When NK cells were purified from WT and Dectin-1-deficient splenocytes and subjected to the in vitro killing assay for B16 cells, a slight decrease in cell killing activity of Dectin-1-defcient NK cells was seen as compared to WT NK cells, indicating an ancillary role of the B16-Dectin-1 signaling in NK cells ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}). *Dectin-1* mRNA expression was indeed observed in NK cells and other innate immune cells ([Figure 2---figure supplement 3B,C](#fig2s3){ref-type="fig"}); however, Dectin-1 expression in NK cells does not account for the above Dectin-1-IRF5 axis as IRF5-deficient NK cells show normal cell killing activity ([Figure 1C](#fig1){ref-type="fig"}; middle panel).

When WT-derived resting NK cells were purified and subjected to the co-culture assay, a marked reduction of NK killing activity was also observed when Dectin-1-deficient CD11b^+^ or CD11c^+^ cells were used in lieu of those from WT mice ([Figure 2C](#fig2){ref-type="fig"}). It is worth noting that, consistent with the results showing the existence of IRF5-independent pathway for the Dectin-1 signaling, the reduction of NK cell killing activity was even more pronounced when CD11b^+^ or CD11c^+^ cells from Dectin-1-deficient mice were subjected to the co-culture assay compared to those from IRF5-deficient mice ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). These observations in toto underscore the involvement of Dectin-1 on DCs and/or macrophages in the full-blown NK-mediated tumoricidal activity. On the other hand, since the NK cell-enhancing activity is not totally abrogated by the absence of Dectin-1 in CD11b^+^ or CD11c^+^ cells ([Figure 2C](#fig2){ref-type="fig"}), there is perhaps contribution of additional innate immune receptor(s) in these cells for NK cell activation ('Discussion').

Loss of tumor growth control in Dectin-1-deficient mice {#s2-4}
-------------------------------------------------------

On the basis of the above observations, we examined the in vivo contribution of Dectin-1 to anti-tumor innate immune responses by challenging WT and Dectin-1-deficient mice with the B16 cell lung metastasis model. As shown in [Figure 2D,E](#fig2){ref-type="fig"}, a marked enhancement of metastasis of B16 cells was seen in the lungs of Dectin-1-deficient mice as compared with those of WT mice. Loss of tumor growth control also occurred when Dectin-1-deficient mice were inoculated subcutaneously with B16 cells ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).

Of note, the metastasis to the lung was significantly more profound than that observed in IRF5-deficient mice ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}); this observation is consistent with the above in vitro data, which shows that the IRF5 pathway contributes partly to Dectin-1 signaling ([Figure 2C](#fig2){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). In addition, the control of lung metastasis of B16 cells is equally lost between WT and Dectin-1-deficient mice when NK cells were depleted prior to tumor challenge ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"}); this result further supports the notion that NK cells are indeed the effector cells and that they need the assistance of DCs and macrophages for which Dectin-1 signaling is critical, in the orchestration for the innate control of tumor cells in vivo.

It is worth noting that no overt difference was observed between WT and Dectin-1-deficient mice in terms of (i) the proportion of splenic NK cells, (ii) production of IFN-γ by NK cells in vitro*,* and (iii) NK cell-dependent clearance of murine cytomegalovirus (MCMV) in vivo ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"}). Therefore, NK cell-dependent immune responses are not globally impaired by the absence of Dectin-1; impairment is selective to the anti-tumor response.

Requirement of N-glycan structures for the recognition of Dectin-1 {#s2-5}
------------------------------------------------------------------

Does Dectin-1 recognize a molecular structure(s) on B16 cells? To address this question, we generated a soluble form of Dectin-1 conjugated to human IgG1 Fc (termed sDectin-1) to detect binding of Dectin-1 to the cell surface. Interestingly, substantial binding of sDectin-1 to B16 cells was detected, whereas binding was almost undetectable to mouse embryonic fibroblasts (MEFs) and other primary, non-transformed cells ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).10.7554/eLife.04177.017Figure 3.Recognition of N-glycan structures on B16F1 cells by Dectin-1 and its requirement for the enhancement of NK cell-mediated killing activity.(**A**) Binding of sDectin-1 to B16F1 cells (left panel) and primary mouse embryonic fibroblasts (MEFs; right panel). The cells (4 × 10^5^ cells) were incubated with human IgG1 Fc (control Fc) or sDectin-1 (fused with the Fc) for flow cytometric analysis. (**B**) Effect of N-glycosidase treatment (left panel) or O-glycosidase in combination with neuraminidase (right panel) on the sDectin-1 binding to B16F1 cells. The cells (4 × 10^5^ cells) were treated with either N-glycosidase (25 U/ml) or O-glycosidase (25 mU/ml) with neuraminidase (250 mU/ml) for 1 hr and then subjected to the sDectin-1 binding assay. These enzymatic reactions were performed under the conditions wherein these cells remain alive. (**C**) The effect of N-glycosidase or O-glycosidase treatment of B16F1 cells on in vitro killing activity of WT splenocytes. B16F1 cells were treated with or without N-glycosidase (25 U/ml) for 1 hr in RPMI medium (left panel) or treated with or without the combination of O-glycosidase (25 mU/ml) and neuraminidase (125 mU/ml) for 1 hr in RPMI medium (right panel) and then subjected to in vitro killing assay. ^51^Cr radioactivity released from target cells was measured. Represented as means ± SD. E/T: effector/target cell ratio. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.017](10.7554/eLife.04177.017)10.7554/eLife.04177.018Figure 3---figure supplement 1.Binding of sDectin-1 to various mouse primary cells.The sDectin-1 binding to splenic CD11b^+^ cells, CD11c^+^ cells, NK cells, liver cells, or lung cells were examined as described in [Figure 3A](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.018](10.7554/eLife.04177.018)10.7554/eLife.04177.019Figure 3---figure supplement 2.Effect of neuraminidase treatment on the sDectin-1 binding to B16F1 cells.B16F1 cells (4 × 10^5^ cells) were treated with or without neuraminidase (250 mU/ml) for 1 hr and then subjected to the sDectin-1 binding assay.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.019](10.7554/eLife.04177.019)10.7554/eLife.04177.020Figure 3---figure supplement 3.Effect of N-glycosidase treatment of B16F1 cells on in vitro killing activity of purified NK cells.B16F1 cells were treated with or without N-glycosidase (25 U/ml) for 1 hr in RPMI medium and then used as target cells for in vitro killing assay with purified NK cells from WT mice. ^51^Cr radioactivity released from the target cells was measured. Represented as means ± SD. E/T: effector/target cell ratio. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.020](10.7554/eLife.04177.020)10.7554/eLife.04177.021Figure 3---figure supplement 4.Mass spectrometric analysis of N-glycosidase-treated B16F1 cells.The supernatant of B16F1 cells treated with N-glycosidase for 1 hr was collected and incubated with protein G-conjugated sepharose bound without (blue peaks) or with (green peaks) sDectin-1. N-glycans remained in the supernatant was then analyzed by mass spectrometry. The intensities of the spectra were normalized to that of glycan corresponding to the peak (m/z; 1159.40).**DOI:** [http://dx.doi.org/10.7554/eLife.04177.021](10.7554/eLife.04177.021)10.7554/eLife.04177.022Figure 3---figure supplement 5.Proposed N-glycan structures detected by mass spectrometric analysis.Proposed structures of N-glycans detected by the mass spectrometric analysis ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}) are depicted.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.022](10.7554/eLife.04177.022)10.7554/eLife.04177.023Figure 3---figure supplement 6.No differences in the amount of each N-glycan structure between samples with and without sDectin-1 treatment.Effect of the incubation of sDectin-1 on the relative amount of N-glycan structures released from N-glycosidase-treated B16F1 cells. Relative amounts of each N-glycan structure to total N-glycan amount in the two samples in [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"} were plotted. Note that no differences are seen in the concentration of each glycan structure between the supernatants with or without treatment with sDectin-1 prior to the mass spectrometry analysis.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.023](10.7554/eLife.04177.023)

Since β-glucans, known ligands of Dectin-1, are not expressed by mammalian cells ([@bib6]), we hypothesized the presence of other types of glycosylated structure(s) on B16 cells that are mediating the recognition by Dectin-1. In this context, it has been shown that enhanced glycosylation levels provide growth advantages to many if not all tumor cells ([@bib15]; [@bib16]). Interestingly, we found that sDectin-1 binding to B16 cells was markedly reduced upon N-glycosidase treatment, while treatment by O-glycosidase or neuraminidase showed only a marginal effect, suggesting there is a major requirement for N-glycan structures to Dectin-1 binding ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Consistent with this, a marked reduction of tumoricidal activity of splenocytes was observed when B16 cells were pretreated with N-glycosidase, whereas O-glycosidase treatment did not affect this activity ([Figure 3C](#fig3){ref-type="fig"}). Further, N-glycosidase treatment of B16 cells did not affect the in vitro killing activity of purified NK cells ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), indicating in toto there is a critical role of Dectin-1 recognition of and signaling by N-glycan structures on tumor cells by DCs and macrophages.

We then investigated the nature of N-glycan structures on B16 cells by subjecting the supernatant generated after N-glycosidase treatment to mass spectrometric (MS) analysis. As reported previously, N-glycan structures, such as N-glycans with β1,6-GlcNAc branching ([@bib12]), the expression of which is increased in tumor cells, were detected. Of note, pretreatment of the supernatant by sDectin-1 did not alter the MS peak pattern ([Figure 3---figure supplements 4--6](#fig3s4 fig3s5 fig3s6){ref-type="fig"}). This observation suggests that N-glycan structures, highly expressed in tumor cells, need to be bound to proteins for the Dectin-1 recognition (See below).

Dectin-1 signaling and gene expression by tumor cells {#s2-6}
-----------------------------------------------------

To address the issue of whether Dectin-1 signaling is required for direct cell-to-cell contact or for the induction of a soluble mediator(s), we examined supernatants from CD11b^+^ or CD11c^+^ cells mixed with B16 cells and found that they had little, if any, effect on NK cell activity ([Figure 4A](#fig4){ref-type="fig"}). In addition, the use of antibodies against type I IFNs or IL12, both cytokines are known to activate NK cells ([@bib9]), showed no effect on the NK cell-enhancing activity by DCs ([Figure 4B](#fig4){ref-type="fig"}). These results support the notion that Dectin-1 signaling is crucial for mediating cell-to-cell contact and subsequent NK activation.10.7554/eLife.04177.024Figure 4.Requirement of cell-to-cell contact between NK cells and DCs for the enhancement of NK cell-mediated killing activity.(**A**) Effect of the supernatant of myeloid cells after incubation with tumor cells. NK cell killing activity against B16F1 cells was assessed in the presence of supernatants from the co-culture of B16F1 cells with splenic CD11b^+^ cells (left panel) or CD11c^+^ cells (right panel). Represented as means ± SD. (**B**) Effect of antibodies against cytokines on NK cell-mediated killing activity. In vitro killing activity of purified NK cells (WT; 1 × 10^5^ cells) against B16F1 cells in the presence of 3 × 10^5^ of splenic CD11c^+^ cells was assessed without or with neutralizing antibodies for type I IFNs or IL12p40. (**C**) Induction of mRNAs in DCs co-cultured with B16F1 cells via Dectin-1 signaling. WT or *Dectin-1*^*−/−*^ splenic CD11c^+^ cells (3 × 10^5^ cells) were co-cultured with B16F1 cells (1 × 10^4^ cells). Total RNA from those cells was then isolated at time zero and 4 hr after the co-culture and then subjected to microarray analysis. We first identified genes for which mRNA is induced more than two-fold in WT DCs co-cultured with B16F1 cells and then, of those, selected the genes whose mRNA levels are increased more than twofold in WT 4 hr sample compared to *Dectin-1*^*−/−*^ 4 hr sample. Those selected genes are listed in the order of fold change (WT 4 hr/*Dectin-1*^*−/−*^ 4 hr) ([Table 1](#tbl1){ref-type="table"}). Genes encoding a membrane-bound protein are listed. (**D**) Induction of *Fam26f* (*Inam*) mRNA by the Dectin-1-IRF5 pathway. The expression levels of *Inam* mRNA were monitored by qRT-PCR analysis of total RNA from splenic CD11c^+^ cells (WT, *Irf5*^−/−^, or *Dectin-1*^*−/−*^; 3 × 10^5^ cells) co-cultured with B16F1 cells (1 × 10^4^ cells) for 4 hr as described in 'Materials and methods'. Results are presented relative to the expression of *Gapdh* mRNA. Represented as means ± SD. \*p \< 0.05 by Student\'s *t* test. NS, not significant. Although the IL15 cytokine system is known to promote growth and activity of NK cells, *Il15* and *Il15ra* mRNA expression levels were affected only marginally in the *Dectin-1*^−/−^ DCs ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). The results suggest that this cytokine system will not be involved in this particular experimental setting. (**E**) Effect of INAM expression in DCs on the enhancement of NK cell killing activity. Purified NK cells (WT; 1 × 10^5^ cells) were mixed with increasing amounts (1 × 10^4^, 3 × 10^4^, and 1 × 10^5^ cells) of INAM-transduced WT BMDCs (BMDC-INAM) or mock-transduced WT BMDCs (control BMDC) and killing activities against B16F1 cells were monitored. Represented as means ± SD. In all in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled B16F1 cells were used. ^51^Cr radioactivity released from target cells was measured. The percentage of cytotoxicity was calculated as described in the legend of [Figure 1D](#fig1){ref-type="fig"} and represented as Net lysis (%).**DOI:** [http://dx.doi.org/10.7554/eLife.04177.024](10.7554/eLife.04177.024)10.7554/eLife.04177.025Figure 4---figure supplement 1.Induction of *Il15* or *Il15ra* mRNAs in DCs co-cultured with B16F1 cells.*Il15* (left panel) or *Il15ra* (right panel) mRNA were monitored by qRT-PCR analysis as described in [Figure 4D](#fig4){ref-type="fig"}. Results are presented relative to the expression of *Gapdh* mRNA. Represented as means ± SD. \*p \< 0.05 by Student\'s *t* test. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.025](10.7554/eLife.04177.025)

We then examined the gene expression profiles of WT or Dectin-1-deficient DCs exposed to B16 cells by microarray analysis and found the induction of a substantial number of genes ([Figure 4C](#fig4){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). The affected genes include several membrane-bound proteins amongst which *Inam* (termed as *Fam26f*) is known to activate NK cells via its homophilic interaction ([@bib11]). Interestingly, the *Inam* mRNA induction by B16 cells is IRF5-dependent in splenic CD11c^+^ cells ([Figure 4D](#fig4){ref-type="fig"}) and lentiviral expression of INAM cDNA in bone marrow-derived DCs resulted in the enhancement of NK cell-mediated killing of B16 cells ([Figure 4E](#fig4){ref-type="fig"}). Thus, the Dectin-1-IRF5-INAM pathway may participate in the DC-mediated activation of NK cells, at least in part, in this experimental setting. Obviously, more detailed analyses will be required to gain further mechanistic insight into the enhancement of NK-mediated tumor control by DCs and macrophages.10.7554/eLife.04177.026Table 1.Induction of mRNAs in DCs co-cultured with B16F1 cells via Dectin-1 signaling**DOI:** [http://dx.doi.org/10.7554/eLife.04177.026](10.7554/eLife.04177.026)UnigeneGene symbolFold changeMm.275426*Amy2a1///Amy2a2///Amy2a3///Amy2a4///Amy2a5*1995.76Mm.45316*Cela2a*173.36Mm.383263*Try4///Try5*88.72Mm.475541*Cela3b///Gm13011*61.79Mm.20407*Pnlip*21.28Mm.142731*Reg1*16.65Mm.34374*Ctrb1*16.42Mm.21160*Clps*14.85Mm.276926*Prss2*13.67Mm.34692*Cpb1*10.25Mm.450553*Tpte*9.99Mm.10753*Pnliprp1*8.31Mm.46360*Reg2*6.86Mm.1825*Tff2*5.19Mm.867*Ccl12///LOC100862578*4.96Mm.464256*Tcl1b3*3.97Mm.2745*Ctrl*3.72Mm.35088Chrnb23.49Mm.14874*Gzmb*3.46Mm.159219*Batf2*3.45Mm.439927*Nol7*3.00Mm.4769Fzd62.85Mm.26760Lrrc192.85Mm.34479*Fam26f* (*Inam*)2.80Mm.4662*Irg1*2.72Mm.4922*Csf2*2.70Mm.2319*Stmn3*2.70Mm.24375*Ttpa*2.70Mm.41416*Rilp*2.65Mm.159575*Cdyl2*2.57Mm.261140*Iigp1*2.44Mm.42791Crtam2.37Mm.26730*Hp*2.32Mm.203866*Ahnak*2.30Mm.34520*Gtpbp8*2.30Mm.32368*Krit1*2.29Mm.116997*Hmmr*2.26Mm.208125*Adamts6*2.17Mm.333734Adora2a2.15Mm.484815Ly6i2.13Mm.271830*Dhx58*2.10Mm.131098*Golga1*2.10Mm.131723*Cxcl11*2.09Mm.5022*Mmp13*2.09Mm.291595*Klf9*2.09Mm.33691*Reg3d*2.08Mm.130*Socs1*2.06Mm.10948*Slfn1*2.05Mm.1062Tnfsf102.04Mm.22213*Glipr2*2.01[^2]

Contribution of Dectin-1 to immune responses against other tumor cells {#s2-7}
----------------------------------------------------------------------

To what extent the Dectin-1-induced anti-tumor immune responses account for other types of tumor cells? To address this issue, we first examined the binding capacity of sDectin-1 for other tumor cell lines. The binding capacity was variable in that the binding was strong for 3LL (lung carcinoma), YAC-1 (lymphoma), and Meth-A (fibrosarcoma) cell lines, but was significantly weaker for some tumor cells such as SL4 (colon carcinoma) and B16F10 (melanoma) cell lines ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). It is worth noting that the latter two cell lines are known to metastasize massively even in WT mice ([@bib34]) (See below).10.7554/eLife.04177.027Figure 5.Dectin-1 binding on other tumor cells and its role in tumor suppression.(**A**) Binding of sDectin-1 to 3LL (left panel) or SL4 cells (right panel). The sDectin-1 binding to these cell lines was examined as described in [Figure 3A](#fig3){ref-type="fig"}. (**B**) In vitro killing activity of WT or *Dectin-1*^*−/−*^ splenocytes against 3LL (left panel) or SL4 cells (right panel) as indicated E/T ratio. Represented as means ± SD. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled target cells were used. (**C**) Quantification of metastasis of 3LL (left panel) or SL4 cells (right panel) in WT or *Dectin-1*^*−/−*^ mice. WT and *Dectin-1*^*−/−*^ mice were intravenously injected with GFP-expressing 3LL (3LL-GFP) or SL4 cells (SL4-GFP). *GFP* mRNA expression levels in lungs were assessed by qRT-PCR 12 (3LL cells) or 14 (SL4 cells) days after the injection. Means are indicated as black bars. \*p \< 0.05 by Student\'s *t* test; ND, none detected; NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.027](10.7554/eLife.04177.027)10.7554/eLife.04177.028Figure 5---figure supplement 1.Binding of sDectin-1 to various mouse cancer cell lines.The sDectin-1 binding to YAC-1 (left panel), Meth-A (middle panel), or B16F10 (right panel) cells were examined as described in [Figure 3A](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.028](10.7554/eLife.04177.028)10.7554/eLife.04177.029Figure 5---figure supplement 2.Pull-down analysis of sDectin-1 binding on cancer cells.B16F1, 3LL, B16F10 and MEF cells (4 × 10^7^ cells) treated with or without N-glycosidase (25 U/ml) for 1 hr were incubated with sDectin-1 (tagged with HA and human IgG1 Fc region), and then the sDectin-1 was chemically cross-linked to the cells. After that, cells were lysed and sDectin-1 was precipitated by protein G-conjugated sepharose. sDectin-1 binding was detected by immunoblot analysis using anti-HA antibody. Arrowhead indicates sDectin-1 protein.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.029](10.7554/eLife.04177.029)10.7554/eLife.04177.030Figure 5---figure supplement 3.In vitro killing activity of WT or *Dectin-1^−/−^* splenocytes against YAC-1 cells.In vitro killing activity of WT or *Dectin-1*^*−/−*^ splenocytes against YAC-1 cells as indicated E/T ratio. ^51^Cr radioactivity released from the target cells was measured. Represented as means ± SD. In in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled YAC-1 cells were used.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.030](10.7554/eLife.04177.030)10.7554/eLife.04177.031Figure 5---figure supplement 4.Contribution of Dectin-1 signaling to anti-tumor killing activity against B16F10 cells.Number of metastasized colonies in lungs from WT or *Dectin-1*^−/−^ mice intravenously injected with 5 × 10^5^ of B16F10 cells. Means are indicated as black bars. NS, not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.031](10.7554/eLife.04177.031)10.7554/eLife.04177.032Figure 5---figure supplement 5.Binding of sDectin-1 to various human cancer cell lines.Binding of human sDectin-1 to HepG2, Huh7, HBC4, HeLa, T98, U251, A549, HCT116, MKN45, PC-3, K562, or G-361 cells was examined as described in [Figure 3A](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.032](10.7554/eLife.04177.032)10.7554/eLife.04177.033Figure 5---figure supplement 6.Induction of *Inam* mRNAs in DCs co-cultured with human cancer cells.Dectin-1-dependent induction of *Inam* (*Fam26f*) mRNA by a human cancer cell line. Mouse splenic CD11c^+^ cells (3 × 10^5^ cells), either from WT mice or *Dectin-1*^−/−^ mice, were co-cultured with HBC4 cells (1 × 10^4^ cells) for 4 hr and total RNA was subjected to qRT-PCR analysis for *Inam* mRNA induction. Results are presented relative to the expression of *Gapdh* mRNA. Represented as means ± SD. \*p \< 0.05 by Student\'s *t* test.**DOI:** [http://dx.doi.org/10.7554/eLife.04177.033](10.7554/eLife.04177.033)

In addition, chemical cross-linking of sDectin-1, followed by immunoblot analysis, generated multiple smear bands of similar pattern using B16F1 and 3LL cells, whereas bands were barely detectable with B16F10 cells or MEFs. Further, these bands are abolished by the pretreatment of cells with N-glycosidase ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Thus, these data suggest that similar or identical N-glycan structures are expressed on multiple proteins that function as Dectin-1 ligands in these, and probably other, Dectin-1 binding tumor cells.

To examine the co-relationship between sDectin-1 binding and NK-mediated killing activity of splenocytes, we selected the lung carcinoma 3LL and YAC-1 cells with strong sDectin-1 binding and colon carcinoma SL4 cells with weak binding, and subjected them to the in vitro killing assay described above. We observed Dectin1-dependent cell killing activity against 3LL and YAC-1 cells ([Figure 5B](#fig5){ref-type="fig"}; left panel and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}), whereas the killing activity of WT splenocytes against SL4 cells was significantly weaker as compared to that for 3LL or YAC-1 cells and was reduced only marginally in Dectin-1-deficient splenocytes ([Figure 5B](#fig5){ref-type="fig"}; right panel). These results support the notion that tumor cells expressing Dectin-1 ligands at high levels are more susceptible to NK cell-mediated killing in a manner dependent on Dectin-1 signaling.

We further expended our in vivo analysis to 3LL and SL4 cells. As shown in [Figure 5C](#fig5){ref-type="fig"}, a marked enhancement of lung metastasis of 3LL cells was observed in Dectin-1-deficient mice, but not in WT mice ([Figure 5C](#fig5){ref-type="fig"}; left panel), while SL4 cells without significant sDectin-1 binding ([Figure 5A](#fig5){ref-type="fig"}; right panel) underwent massive metastasis in both WT and mutant mice ([Figure 5C](#fig5){ref-type="fig"}; right panel). Expectedly, massive metastasis of B16F10 cells was observed without significant difference between WT and Dectin-1-deficient mice ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}), suggesting that B16F10 cells could have been selected to evade the Dectin-1-mediated anti-tumor orchestration. Thus, these in vivo observations are consistent with in vitro observations in that the recognition of and signaling by Dectin-1 in DCs and macrophages constitute a critical aspect of the NK cell-mediated anti-tumor innate immunity.

Finally, Dectin-1 binding to human tumor cell lines was examined by preparing a human sDectin-1. Interestingly, we found human sDectin-1 binds to several of these cell lines ([Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}). We also observed the Dectin-1-dependent induction of *Inam* mRNA in mouse DCs by human cancer cell line HBC4, to which human sDectin-1 strongly binds ([Figure 5---figure supplement 6](#fig5s6){ref-type="fig"}). Since mouse and human Dectin-1 are highly conserved, we infer the mouse DCs respond to human Dectin-1 ligands for gene induction. As such, these results suggest the presence of a similar or identical anti-tumor Dectin-1 signaling mechanism in the human immune system.

Discussion {#s3}
==========

The critical role of signal-transducing innate immune receptors in mediating innate and adaptive immune responses against invading pathogens is well known. However, it has been enigmatic if and how these receptors contribute to anti-tumor responses. In the present study, we demonstrated that the innate immune receptor Dectin-1 expressed on DCs and macrophages is important to NK-mediated killing of tumor cells. Our results indicate that NK cells are required to orchestrate with DCs and macrophages for cell killing, wherein activation of the IRF5 transcription factor by Dectin-1 signaling instigated by receptor recognition of N-glycan structures on tumor cells is critical. This notion is supported by an excessive growth of tumors with sDectin-1 binding in mice genetically deficient in either Dectin-1 or IRF5 in vivo. To our knowledge, this is the first demonstration that an innate immune receptor contributes to anti-tumor recognition and signaling through orchestration of innate immune cells. Our study offers new insight into the NK-mediated anti-tumor activity of the innate immune system (model depicted in [Figure 6](#fig6){ref-type="fig"}).10.7554/eLife.04177.034Figure 6.Schematic view of the orchestration of innate immune cells for NK cell-mediated tumor killing.Dectin-1 expressed by DCs and macrophages recognizes N-glycan structures on tumor cells and signals to activate IRF5 pathway and other pathways, thereby activating NK cells. Thus, NK cells require tumor recognition and signaling by these innate immune cells for their effective tumoricidal action. Although INAM is depicted here, the DC-mediated activation of NK cells would involve other molecules and this Dectin-1-IRF5-INAM pathway may represent only a part of the entire picture. It remains to be further characterized as to whether and how this and/or other effector ligands induced by Dectin-1 signaling contribute to NK activation in full. It is possible that DCs/macrophages are secondarily activated by yet unknown factors from NK cells (see dashed arrow).**DOI:** [http://dx.doi.org/10.7554/eLife.04177.034](10.7554/eLife.04177.034)

A more detailed structural analysis of the Dectin-1 ligand(s) needs to be clarified. Our sDectin-1 chemical cross-linking data suggest that similar or identical N-glycan structures are expressed on multiple protein molecules in tumor cells as Dectin-1 ligands. On the basis of the MS and chemical cross-linking data ([Figure 3---figure supplement 4--6](#fig3s4 fig3s5 fig3s6){ref-type="fig"}, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), we infer that N-glycan structures need to be bound to proteins for the Dectin-1 recognition.

Obviously further work will be required to discern the detailed nature of the ligands, it is possible that Dectin-1 recognition of and activation by N-glycan structures are contingent on the absolute expression levels of N-glycans and/or their associated proteins on the cell; that is, tumor cells with 'increased self' molecules are targets for innate recognition for activation of the immune system. However, it is also possible that Dectin-1 recognition requires particular, tumor-specific N-glycan-containing structures, which may belong to 'altered self' ([@bib33]). Whichever the case, Dectin-1-binding structures may fit into the category of 'tumor-associated molecular patterns (TAMPs)' vis-à-vis PAMPs for invading pathogens and DAMPs for normal cells subjected to stress or death ([@bib43]; [@bib28]). This issue obviously merits more advanced study.

Our data showing that Dectin-1-deficiency does not entirely abrogate the NK-enhancing activity of CD11b^+^ or CD11c^+^ cells suggests the interesting possibility that other CLRs are also involved in the orchestration of innate immune cells for the efficient NK cell-mediated anti-tumor immune response. It is curious that in many tumor cells glycosylation levels are generally enhanced, providing an advantage to tumor cells in migration and metastasis ([@bib15]; [@bib16]). If so, the host\'s innate system could have evolved to limit the immune evasion of tumor development through recognition of glycosylation products via Dectin-1 and other CLR family members. As such, the potential involvement of other CLR members in the recognition tumor cells, to which sDectin-1 binding is low, is also an interesting future issue to be addressed.

The examination of the role of Dectin-1 and other CLRs in the control of tumors in de novo carcinogenesis models will be an exciting issue to address in future studies. It is interesting to note that Dectin-1 mRNA is also expressed in CD11b^+^ or CD11c^+^ cells from liver and lung ([Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}); hence, we infer that Dectin-1 signaling may contribute to the control of tumor progression in various tissues. In addition, since tumor cells are phenotypically and functionally heterogeneous even within the same tumor mass ([@bib32]), it is possible that tumor cells show a differential expression profiles for Dectin-1 ligands in vivo. If so, it may be the case that the in vivo progression of a tumor is controlled via direct and indirect Dectin-1 signaling, that is, NK cells activated by CD11b^+^ or CD11c^+^ cells via Dectin-1 signaling may exert tumoricidal activities on tumor cells regardless on their Dectin-1 ligand expression. Obviously, these possibilities are speculative and need to be investigated further.

Identification of critical target molecules of Dectin-1 signaling that participate to the enhancement of NK cells for anti-tumor response is also an interesting, though unanswered question. Although our study suggests the involvement of INAM, we infer that other membrane molecules identified here ([Figure 4C](#fig4){ref-type="fig"}), which are without a known function at present, may also participate. This is obviously an important future issue to be rigorously addressed.

Our present study may also offer a novel view on the clinical efficacy of monoclonal antibodies (Abs) such as cancer therapeutics, specifically for how Ab-dependent cell-mediated cytotoxicity (ADCC) mediates antitumor cytotoxicity via Fc receptor(s) on immune cells ([@bib1]; [@bib47]). Although the conventional wisdom has been that Fc receptors (FcRs) expressed on NK cells are responsible for ADCC, primarily based on in vitro studies using human mononuclear cells ([@bib1]; [@bib47]), it has been appreciated for some time that in the mouse, Ab mediated tumor killing is mediated primarily by myeloid cells. For example, mouse IgG2a is the most potent Ab isotype for the activation of effector cells through its intermediate--affinity interaction with FcRIV ([@bib38]; [@bib40]). Yet, this FcR is not expressed by NK cells, but is expressed by DCs and macrophages ([@bib39]). It is also interesting to note that FcRIV utilizes FcRγ, the FcR common γ subunit, to transmit the Ab signal to the cell interior via pathways similar, if not identical, to those of CLRs ([@bib20]). As such, Abs may activate DCs and macrophages via FcRIV-FcRγ pathway to mediate both ADCC and further contribute to NK cell activation through a mechanism similar to the pathway we describe in this study. The process may be termed 'indirect ADCC'. Clearly, Ab-mediated cancer therapeutics likely involves multiple mechanisms ([@bib48]); therefore, our speculation obviously needs further investigation, particularly in the context of human cancer therapeutics.

Finally, in light of the tenet that innate immunity instructs adaptive immunity ([@bib25]), our study may also raise an interesting issue of whether Dectin-1 signaling by tumor recognition also affects adaptive anti-tumor immune responses, and also may provide new means for the efficient immune responses for cancers such as Dectin-1 agonistic Abs.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

C57BL/6 mice were from CLEA Japan Inc. *Clec7a (Dectin-1)*^*−/−*^, *Irf3*^*−/−*^, *Irf5*^*−/−*^, *Irf7*^*−/−*^, *Rag1*^*−/−*^, and *Myd88*^*−/−*^ mice as described previously were maintained on a C57BL/6 genetic background ([@bib45]; [@bib22]; [@bib51]; [@bib19]; [@bib44]; [@bib27]). CD11c-DTR and C57BL/6-Ly5.1 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Each experiment was performed using sex-, age-matched mice. All animal care and experiments conformed to the guidelines for animal experiments of the University of Tokyo, and were approved by the animal research committee of the University of Tokyo (Reference number: P10-122 and P10-123).

Reagents {#s4-2}
--------

Curdlan was purchased from Wako Chemicals (Japan). FK506 was from Enzo Life Sciences (Farmingdale, NY). N-glycosidase, O-glycosidase, and neuraminidase were from Roche Diagnostics (Switzerland). Anti-IFN-α (4E-A1) and anti-IFN-β (7F-D3) monoclonal antibodies were purchased from YAMASA (Japan). Anti-IL12p40 antibody (C17.8), APC-conjugated anti-CD49b antibody (DX5), APC-conjugated anti-CD11b antibody (M1/70), APC-conjugated anti-CD11c antibody (N418), and FITC-conjugated anti-F4/80 antibody (BM8) were from Biolegend (San Diego, CA). FITC-conjugated anti-CD3ε antibody (145-2C11) was from BD Biosciences (San Jose, CA).

Cells {#s4-3}
-----

Mouse melanoma cell line B16F1 cells and B16F10 cells, Lewis lung carcinoma cell line 3LL cells, fibrosarcoma cell line Meth-A cells, and HEK293T cells were obtained from RIKEN BioResource Center (Japan). Mouse colon carcinoma cell line SL4 cells were kindly provided by Dr T Irimura (The University of Tokyo). B16F1 cells, B16F10 cells, and HEK293T cells were maintained in Dulbecco\'s Modified Eagle\'s Medium (DMEM; Nissui, Japan) supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT). SL4 cells were cultured in DMEM-F12 medium (Gibco/Invitrogen, Grand Island, NY) supplemented with 10% FCS. 3LL cells and Meth-A cells were cultured in RPMI medium (Nacalai Tesque, Japan) supplemented with 10% FCS. Mouse lymphoma cell line YAC-1 cells were cultured as described previously ([@bib46]). Primary mouse embryonic fibroblasts were isolated and cultured as described previously ([@bib54]).

Human hepatocellular carcinoma cell line HepG2 cells and melanoma cell line G-361 cells were obtained from National Institute of Biomedical Innovation (Japan). Human cervical carcinoma cell line HeLa cells, lung adenocarcinoma cell line A549 cells, colorectal carcinoma cell line HCT116 cells, gastric carcinoma cell line MKN45 cells, prostate cancer cell line PC-3 cells, and chronic myelogenous leukemia cell line K562 cells were obtained from RIKEN BioResource Center. Human breast cancer cell line HBC4 cells were kindly provided by Dr K Yamazaki (Cancer Institute Hospital of JFCR, Japan). Human hepatoma cell line Huh7 cells were kindly provided by Dr M Kohno (Toray Co.). Human glioblastoma cell lines T98 cells and U251 cells were kindly provided by Dr J Yoshida (Nagoya University). HepG2 cells, Huh7 cells, HeLa cells, T98 cells, A549 cells, and HCT116 cells were maintained in DMEM supplemented with 10% FCS. HBC4 cells, MKN45 cells, PC-3 cells, and K562 cells were cultured in RPMI medium supplemented with 10% FCS. U251 cells were maintained in DMEM supplemented with 10% FCS and non-essential amino acids (Nacalai Tesque). G-361 cells were cultured in McCoy\'s 5A medium (Gibco/Invitrogen) supplemented with 10% FCS. Mycoplasma contaminations of cell lines were checked by MycoAlert Mycoplasma Detection Kit (Lonza, Switzerland) according to manufacturer\'s instruction; no evidence of contamination was found.

To prepare splenocytes, spleens were digested with collagenase D (Roche Diagnostics) and DNase I (Roche Diagnostics) as described previously ([@bib37]). Splenic CD11b^+^, CD11c^+^, B, or T cells were purified using CD11b or CD11c MicroBeads, B cell isolation kit, or pan T cell isolation kit II, respectively (Miltenyi Biotec, Germany). For CD8^+^CD11c^+^ or CD8^−^CD11c^+^ cell purification, cells were negatively selected from splenocytes using anti-mouse CD90.2 (30-H12; eBioscience, San Diego, CA), anti-mouse CD5 (53-7.3; eBioscience), and anti-mouse B220 (RA3-6B2; eBioscience) antibodies with Dynabeads M-280 sheep anti-mouse IgG (Invitrogen), and CD19 and CD49b (DX5) MicroBeads (Miltenyi Biotec). CD8^+^CD11c^+^ and CD8^−^CD11c^+^ cells were selected using CD8a (Ly-2) and CD11c MicroBeads (Miltenyi Biotec). CD11c^−^CD11b^+^ cells were purified using CD11b Microbeads from splenocytes of CD11c-DTR mice after depletion of CD11c^+^ cells by intraperitoneal injection of diphtheria toxin ([@bib26]) (4 ng/g body weight; Sigma, St Louis, MO). For NK cells purification, splenocytes were incubated within nylon-wool column (Wako Chemicals) for 1 hr, and then NK cells were negatively isolated from the nylon-non-adherent cells with NK cell isolation kit II (Miltenyi Biotec) as described previously ([@bib52]). For NK cell depletion, mice were injected intraperitoneally with 200 µg anti-asialo GM1 antibody (Wako Chemicals). For liver cell and lung cell preparation, livers and lungs were digested with collagenase D and DNase I, passed through a sterile 40 µm pore size nylon cell strainer (BD Biosciences) and the cell suspensions were treated with RBC lysis buffer (eBioscience). To purify CD11b^+^ and CD11c^+^ cells from livers and lungs, the cell were stained with APC-conjugated anti-CD11b antibody and FITC-conjugated anti-F4/80 antibody or APC-conjugated anti-CD11c antibody. CD11b^+^F4/80^+^ cells and CD11c^+^ cells were sorted using FACSAria (BD Biosciences). To generate bone marrow-derived dendritic cells (BMDCs), bone marrow cells were cultured with 20 ng/ml mouse GM-CSF (BD Pharmingen, San Diego, CA) in RPMI medium supplemented with 10% FCS for 6 days.

Lung metastasis assay {#s4-4}
---------------------

Mice were intravenously injected with 1 × 10^6^ or 2 × 10^6^ of B16F1 cells, 1 × 10^6^ of 3LL-GFP cells, 3 × 10^5^ of SL4-GFP cells, or 5 × 10^5^ of B16F10 cells. For B16F1 cells and B16F10 cells, the number of metastatic colonies in lungs was counted after 14 days of injection. Lungs were harvested 12 (3LL-GFP cells) or 14 (SL4-GFP cells) days after injection. Total RNA was purified from lungs and subjected to quantitative reverse transcription PCR (qRT-PCR) to measure *GFP* mRNA expression level. GFP-expressing 3LL cells and SL4 cells (3LL-GFP cells and SL4-GFP cells) were established using retrovirus-mediated gene transfer system as described previously ([@bib35]). pMX-GFP retrovirus expression vector was kindly provided by Dr T Kitamura (The University of Tokyo).

Subcutaneous tumor growth assay {#s4-5}
-------------------------------

Mice were injected subcutaneously with 1 × 10^5^ of B16F1 cells. Tumor volume was evaluated using the equation volume = πab^2^/6, where a and b are the lengths of the major and minor axes, respectively ([@bib23]).

Bone marrow transplantation {#s4-6}
---------------------------

Bone marrow transplantation was performed as described previously ([@bib21]). Briefly, recipient mice were subjected to sublethal γ-irradiation (5 Gy × 2 with a 3-hr interval), and were injected with 5 × 10^6^ of bone marrow cells freshly isolated from donor mice. 3 months after the transplantation mice were subjected to metastasis assay. All mice showed a high-degree chimerism (90--95%).

In vitro killing assay {#s4-7}
----------------------

Killing activity of NK cells was tested by ^51^Cr release assay ([@bib52]). Splenocytes or NK cells were prepared from WT, *Irf5*^*−/−*^*,* or *Dectin-1*^−/−^ mice and used as effector cells. Target cells suspended in RPMI medium were incubated with 100 µCi Na~2~^51^CrO~4~ (Perkin Elmer, Waltham, MA) for 1 hr at 37°C and washed with PBS (Nacalai Tesque) three times. Target cells were then mixed with effector cells at the indicated effector/target (E/T) ratios in flat-bottomed 96-well plates with a total volume of 200 µl and then co-cultured for 4 hr at 37°C. In all in vitro killing assays, 1 × 10^4^ of ^51^Cr-labeled target cells were used. Released ^51^Cr radioactivity in the supernatants was measured with a Wallac 1480 Wizard 3′′ gamma counter (Perkin Elmer). The percentage of cytotoxicity was calculated as following formula: specific lysis (%) = (experimental release − spontaneous release)/(maximum release − spontaneous release) × 100. Target cell lysis was also measured by co-culturing target cells with myeloid cells in the absence of NK cells. This background value was subtracted from the total values obtained in the presence of NK cells and the calculated percentage of cytotoxicity was represented as Net lysis (%). All experiments were performed at least three times and the results were highly reproducible. We also confirmed there was no discernible phagocytosis by myeloid cells in our killing assays.

Immunoblotting assay {#s4-8}
--------------------

Immunoblotting assay was performed as described previously ([@bib55]). Antibodies for IRF5 and USF-2 were purchased from Cell Signaling (Danvers, MA) and Santa Cruz (Santa Cruz, CA), respectively. USF-2 was used as a nuclear marker protein.

qRT-PCR {#s4-9}
-------

Total RNA from tissues or cells was extracted using RNAiso (TAKARA, Japan) or NucleoSpin RNA II (MACHEREY NAGEL, Germany), and was reverse-transcribed with PrimeScript RT Master Mix (TAKARA). qRT-PCR was performed on Light Cycler 480 (Roche Bioscience) using the SYBR Green PCR Master Mix (Roche Bioscience) and values were normalized to the expression of *Gapdh* mRNA as described previously ([@bib54]). Primer sequences are as follows: *Gapdh* forward 5′-ctcatgaccacagtccatgc-3′; *Gapdh* reverse 5′-cacattgggggtaggaacac-3′; *Clec7a* forward 5′-catcgtctcaccgtattaatgcat-3′; *Clec7a* reverse 5′-cccagaaccatggccctt-3′; *Gzmb* forward 5′-accaaacgtgcttcctttcg-3′; *Gzmb* reverse 5′-tttggtgaaagcacgtggag-3′; *Prf1* forward 5′-tctccccactctggtttcca-3′; *Prf1* reverse 5′-gagatggggcagacacttgg-3′; *Ifng* forward 5′-tggctttgcagctcttcctc-3′; *Ifng* reverse 5′-tccttttgccagttcctcca-3′; *Il6* forward 5′-acgatgatgcacttgcagaa-3′; *Il6* reverse 5′-gtagctatggtactccagaagac-3′; *Tnf* forward 5′-tcataccaggagaaagtcaacctc-3′; *Tnf* reverse 5′-gtatatgggctcataccagggttt-3′; *Fam26f* forward 5′-gacacagttggccgaagaga-3′; *Fam26f* reverse 5′-aacgctgagatttcctgcca-3′; *GFP* forward 5′-cttcttcaagtccgccatgc-3′; *GFP* reverse 5′-gtgtcgccctcgaacttcac-3′; *Il15* forward 5′-catccatctcgtgctacttgtg-3′; *Il15* reverse 5′-gcctctgttttagggagacct-3′; *Il15ra* forward 5′-gctgacatccgggtcaagaa-3′; *Il15ra* reverse 5′-cacttgaggctgggagttgt-3′. All experiments were performed at least three times in triplicate.

ELISA {#s4-10}
-----

Purified NK cells (WT or *Dectin-1*^−/−^; 5 × 10^4^ cells) were stimulated with 10 or 100 ng/ml of recombinant mouse IL12 (R&D Systems, Minneapolis, MN). IFN-γ production in culture supernatants was evaluated by ELISA kit (R&D Systems) after 24-hr incubation.

MCMV preparation and infection {#s4-11}
------------------------------

Mouse cytomegalovirus (MCMV; Smith strain) was purchased from ATCC. MCMV stocks were prepared as described ([@bib7]). Briefly, MEFs were infected with MCMV and incubated for 72 hr until the cell layer was completely infected. Then, the cells and supernatant were collected and were subjected to three freeze-and-thaw cycles to release cell-associated virus. The crude virus-containing medium was centrifuged and filtrated with a sterile 0.45 µm pore size filter (Millipore, Billerica, MA). MCMV in the filtrated medium was concentrated by centrifugation at 26,000×*g* (15,000 rpm; Beckman SW 41 Ti rotor) for 3 hr at 4°C. The pellet was resuspended in PBS and filtrated through a sterile 0.45 µm filter. MCMV titer was determined by plaque-forming cell assay. MEFs were infected with serially diluted (log~10~ steps) virus stock solution or organ homogenates and incubated for 2 hr at 37°C. Then, the cells were washed extensively and cultured in 2.4% methylcellulose-containing DMEM supplemented with 4% FCS for 5 days. After incubation, cells were fixed with formalin and stained with crystal violet solution. Virus plaques were then counted. WT and *Dectin-1*^*−/−*^ mice were intraperitoneally infected with MCMV (5 × 10^3^ or 3 × 10^5^ pfu). For NK depletion, WT mice were given anti-asialo GM1 antibody intravenously one day before infection. Mice were sacrificed at 3 days postinfection and spleens from the mice were excised and homogenized in PBS.

Preparation of a soluble form of Dectin-1 (sDectin-1) protein {#s4-12}
-------------------------------------------------------------

The DNA fragment encoding extracellular domain (amino acid residues 73--244) of murine Dectin-1 was cloned using forward primer 5′-aaagatcttacccatacgatgttccagattacgctaattcagggagaaatc-3′ and reverse primer 5′-aaaaatctagacagttccttctcacagatac-3′, and inserted into the *Bgl*II sites of pFUSE-hIgG1-Fc2 vector (Invivogen, San Diego, CA), to make HA-tagged murine sDectin-1 (msDectin-1) conjugated with human IgG1 Fc region ([@bib18]). The DNA fragment encoding extracellular domain (amino acid residues 73--247) of human Dectin-1 was cloned using forward primer 5′-agatcttacccatacgatgttccagattacgctaattcaggaagcaacacattgg-3′ and reverse primer 5′-agatctcattgaaaacttcttctcac-3′ to make HA-tagged human sDectin-1 (hsDectin-1) conjugated with human IgG1 Fc region. HEK293T cells were transfected with pFUSE-hIgG1-Fc2-HA-msDectin-1, pFUSE-hIgG1-Fc2-HA-hsDectin-1, or pFUSE-hIgG1-Fc2 empty vector using X-tremeGENE 9 DNA Transfection Reagent (Roche Applied Science). Then, supernatants were filtrated and gently mixed with Protein A Sepharose Fast Flow (GE Healthcare, Waukesha, WI). The mouse sDectin-1, human sDectin-1, or human IgG1 Fc (control Fc) was eluted with 100 mM Glycine-HCl (pH 3.0), dialyzed with PBS, and concentrated using Amicon Ultra centrifugal filter (Millipore).

Flow cytometric assay {#s4-13}
---------------------

Cells were incubated with sDectin-1 or human IgG1 Fc in TBS (pH 8.0) containing 1.3 mM CaCl~2~ for 15 min at 4°C, and then labeled with anti-human IgG1 antibody (4E3; Abcam, Cambridge, MA) conjugated with allophycocyanin (APC). The cells were then analyzed by LSRII/Fortessa (BD Biosciences). APC conjugation to anti-human IgG1 antibody was performed using APC Labeling Kit-NH~2~ (Dojindo, Japan) according to the manufacturer\'s protocol.

Glycan analysis {#s4-14}
---------------

After B16F1 cells (1 × 10^7^ cells) were treated with N-glycosidase (25 U/ml) for 1 hr, the supernatant was collected and incubated at 75°C for 15 min to inactivate N-glycosidase. Then, the supernatant was treated with or without sDectin-1 and Protein G Sepharose 4 Fast Flow (GE Healthcare). N-glycans remained in the supernatant were analyzed by Glycan*MAP* (Ezose Science, Pine Brook, NJ) ([@bib14]).

Microarray analysis {#s4-15}
-------------------

Microarray analysis was performed as described previously ([@bib36]). WT or *Dectin-1*^−/−^ splenic CD11c^+^ cells (3 × 10^5^ cells) were co-cultured with B16F1 cells (1 × 10^4^ cells) for 4 hr. Total RNA was extracted from co-cultured B16F1 cells and CD11c^+^ cells and analyzed by GeneChip Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA).

Lentivirus-mediated gene transfer {#s4-16}
---------------------------------

pCSII-EF-MCS-IRES2-Venus (pCSII-EF), pMDLg/pRRE, and pCMV-VSV-G-RSV-Rev vector were kindly provided by Dr H Miyoshi (RIKEN). Mouse INAM cDNA was cloned by PCR using primers (Forward 5′-gtcgacatggaaaagttcaaggcagtg-3′, Reverse 5′-gcggccgctcatagttcgtgagtgttagtcat-3′) and inserted into pT7-Blue T-vector (TAKARA). The cDNA was excised by *Xho*I and *Not*I digestion, blunted, and inserted into the blunted *Not*I site of pCSII-EF-MCS-IRES2-Venus vector (pCSII-EF-INAM). A total of 5 × 10^6^ HEK293T cells were seeded on 10-cm dishes 24 hr prior to transfection. pCSII-EF (6 µg) or pCSII-EF-INAM (6 µg) vector in combination with pMDLg/pRRE (6 µg) and pCMV-VSV-G-RSV-Rev (6 µg) vectors was co-transfected into HEK293T cells. The medium was replaced after 4 hr. The lentivirus-containing medium was collected after another 48 hr, cleared by low-speed centrifugation, and filtrated through 0.45 µm filter. Virus particles were concentrated by ultracentrifugation at 70,000×*g* (25,000 rpm; Beckman SW 41 Ti rotor) for 90 min at 4°C. The pellet was resuspended in RPMI supplemented with 10% FCS and filtrated through a sterile 0.45 µm filter, and the viral solution was subdivided to store at −80°C. The transduction efficiency was assessed by fluorescence of Venus ligated in the lentivirus vector, and the frequency of positive cells determined by flow cytometry in comparison with that of non-infected cells. Briefly, serially diluted viral solution was added to BMDCs (3 × 10^5^ cell/500 µl of RPMI medium supplemented with 10% FCS with 4 µg/ml polybrene \[Sigma\] in 24-well plate), centrifuged at 1200×*g* (2360 rpm; TOMY LX-141) for 90 min at 30°C, and incubated for 3 hr. These cells were cultured for 20 hr additionally in fresh medium after wash. Then, the fluorescence intensities of the cells were analyzed by flow cytometry. The appropriate viral titer was determined so as to reach 90% Venus expression in BMDCs and was used for the experiments.

Pull-down of Dectin-1 ligand {#s4-17}
----------------------------

B16F1 and 3LL cells (4 × 10^7^ cells) treated with or without N-glycosidase (25 U/ml) and B16F10 cells and MEFs (4 × 10^7^ cells) treated without N-glycosidase were incubated with sDectin-1. After the unbound sDectin-1 was washed out with PBS, sDectin-1 and its ligand on these cells were cross-linked by Sulfo-NHS-LC-Diazirine (Thermo Scientific, Waltham, MA) according to manufacturer\'s instruction. Cells were lysed in T-PER Tissue Protein Extraction Reagent (Thermo Scientific), followed by the immunoprecipitation with Protein G Sepharose 4 Fast Flow (GE Healthcare). After elution with 100 mM Glycine-HCl (pH 3.0), sDectin-1-ligand complex was detected by Immunoblotting assay using HA-probe (F-7) HRP (Santa Cruz Biotechnology).

Statistical analysis {#s4-18}
--------------------

Data are expressed as mean ± SD Student\'s *t* test was performed and difference was considered to be statistically significant when p-value \< 0.05.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses" for consideration at *eLife*. Your article has been favorably evaluated by K VijayRaghavan (Senior editor) and 3 reviewers, two of whom are members of our Board of Reviewing Editors.

The Reviewing editor was Ruslan Medzhitov. The other two reviewers have agreed to reveal their identity and were Jeffrey Ravetch and Xuetao Cao.

We are very happy to see this accepted for publication by *eLife*. However, in a resubmission please address, where appropriate, the minor comments of the reviewers:

1\) The authors show that Dectin-1 in DC is required for NK cell-mediated anti-tumor activity, and Dectin-1 is dispensable for production of IFN-γ by purified NK cells alone. It\'s not shown whether Dectin-1 signal in DC is involved in NK cell expression of inflammatory and cytotoxic mediators in the co-culture system.

2\) Did the authors detect the regulation of NK cell-mediated tumor cell lysis by DC in a transwell system?

3\) Could the authors show the binding between Dectin-1 on DC and N-glycan on tumor cells in confocal images?

4\) Liver is endowed with regulatory immune function. It is well known that liver is enriched in NK cells, and the chronic inflammation (especially virus infection-induced inflammation) may be involved in the pathogenesis of hepatocellular carcinoma. Do Kupffer cells express Dectin-1? If so, does Dectin-1 in Kupffer cells affect NK cell-mediated anti-tumor responses? The authors should discuss this possible application of the findings of innate receptors in the control of liver cancer.

5\) Upon activation by DC recognition of N-glycan structures in tumor via Dectin-1, do the activated NK cells selectively kill the N-glycan-expressing cells of same origin? Could the authors discuss this?

10.7554/eLife.04177.036

Author response

*1) The authors show that Dectin-1 in DC is required for NK cell-mediated anti-tumor activity, and Dectin-1 is dispensable for production of IFN-γ by purified NK cells alone. It\'s not shown whether Dectin-1 signal in DC is involved in NK cell expression of inflammatory and cytotoxic mediators in the co-culture system*.

We agree with the reviewers that this is an interesting issue to address further. Accordingly, we examined mRNA expression levels for typical inflammatory and cytotoxic mediators in the co-culture system, wherein the ratio of B16F1 cells, DCs, and NK cells is 1:30:10. Total RNA was isolated at zero time and 4 hrs after the co-culture and subjected to qRT-PCR analysis. We found that the mRNA levels for inflammatory cytokines, namely, IFN-g, IL-6, TNF-a remained unchanged between the co-culture with WT DCs and Dectin-1-deficient DCs. Moreover, we did not find any differences in mRNA expression for cytotoxic mediators such as granzyme B and perforin-1. These results are now presented as [Figure 2--figure supplement 8](#fig2s8){ref-type="fig"}. As such, from these analyses, it seems unlikely that Dectin-1 signaling in DCs affects the expression of these molecules in NK cells. We agree that how NK cells are activated by DCs and macrophages that received Dectin-1 signaling to exert their anti-tumor cytotoxicity is a very interesting issue, but hope that the reviewer will agree that this out of the main scope of our present study.

2\) Did the authors detect the regulation of NK cell-mediated tumor cell lysis by DC in a transwell system?

We have not examined the DC effect on NK cells in the transwell system. However, two experiments were carried out to examine the potential involvement of soluble mediators in the DC-mediated activation of NK cells. First, we examined supernatants from CD11b^+^ or CD11c^+^ cells mixed with B16 cells and found that they essentially had no effect on NK cell activity ([Figure 4A](#fig4){ref-type="fig"}). Second, antibodies against type I IFNs or IL12, both known as the potent cytokines for NK cell activation, showed no effect on the NK cell-enhancing activity by CD11c^+^ cells ([Figure 4B](#fig4){ref-type="fig"}). Taken together, these results support the notion that Dectin-1 signaling is crucial for mediating cell-to-cell contact and subsequent NK activation. In addition, we found no difference between WT and Dectin-1^-/-^ DCs in the mRNA induction levels for IL15 or IL15Ra ([Figure 4--figure supplement 1](#fig4s1){ref-type="fig"}). As such, we think it is most likely that Dectin-1 signaling is crucial for mediating cell-to-cell contact between DCs/macrophages and tumor cells and that this contact leads to NK activation. However, we cannot exclude the possibility that DCs/macrophages are secondarily activated by yet unknown factors from NK cells in the actual co-culture situation. Therefore, in order to make this point clearer, we revised the summary figure ([Figure 6](#fig6){ref-type="fig"}), describing the possibility of bidirectional activation between DCs/macrophages and NK cells. This point is also mentioned in the legend of [Figure 6](#fig6){ref-type="fig"}.

3\) Could the authors show the binding between Dectin-1 on DC and N-glycan on tumor cells in confocal images?

We agree that this is potentially a very interesting experiment. However, we find that the following two elements make such an experiment difficult. First, N-glycan structures on tumor cells are likely to be diverse (see [Figure 3--figure supplement 4--6](#fig3s4 fig3s5 fig3s6){ref-type="fig"}) and a suitable tool antibody is essentially not available. Second, Dectin-1 *per se* is also an N-glycosylated protein. As such, although interesting, we hope that the reviewers agree that we cannot perform this experiment.

*4) Liver is endowed with regulatory immune function. It is well known that liver is enriched in NK cells, and the chronic inflammation (especially virus infection-induced inflammation) may be involved in the pathogenesis of hepatocellular carcinoma. Do Kupffer cells express Dectin-1? If so, does Dectin-1 in Kupffer cells affect NK cell-mediated anti-tumor responses? The authors should discuss this possible application of the findings of innate receptors in the control of liver cancer*.

In response to these comments, we isolated macrophages and DCs from liver and lung, and examined the mRNA expression levels for Dectin-1 by qRT-PCR, as we previously examined in these cells from the spleen. Perhaps expectedly, *Dectin-1* mRNA expression was also observed in these cells, and these new data is now presented in [Figure 2--figure supplement 3C](#fig2s3){ref-type="fig"}. Therefore, it is likely that Dectin-1 signaling in DCs and macrophages contributes to control of tumor progression in various tissues including lung and liver, as the reviewer pointed out. We discuss this point in the light of this data in the text as follows "we infer that Dectin-1 signaling may contribute to the control of tumor progression in various tissues."

5\) Upon activation by DC recognition of N-glycan structures in tumor via Dectin-1, do the activated NK cells selectively kill the N-glycan-expressing cells of same origin? Could the authors discuss this?

This is a very interesting point, although difficult to address experimentally. We think it is possible that once NK cells are activated by DCs/macrophages via Dectin-1 signaling, these NK cells will exert more potent tumoricidal activities on other tumor cells that do not express Dectin-1 ligands. Since it has been shown that tumor cells are phenotypically and functionally heterogeneous even in a given tumor mass (Meacham CE and Morrison SJ, *Nature*, 501, 328--337, 2013), it is possible that tumor cells show different expression profiles with each other for Dectin-1 ligands *in vivo*. If so, an interesting possibility is that those tumor cells, expressing Dectin-1 ligands, effectively induce DC/macrophage-mediated NK cell activation and that these so-called "licensed" NK cells may exert tumoricidal activities on tumor cells regardless on their Dectin-1 ligand expression. We thank the reviewers for pointing this out and we now discuss this possibility in the Discussion.

[^1]: These authors contributed equally to this work and are listed in alphabetical order.

[^2]: The genes identified in the microarray analysis in [Figure 4C](#fig4){ref-type="fig"} are listed in the order of fold change (WT 4 hr/*Dectin-1*^*−/−*^ 4 hr). Genes encoding a membrane-bound protein are indicated in red letters.
